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PRE-TRANSFUSION TESTING FOR THE 
CHRONICALLY TRANSFUSED, SENSITIZED PATIENT 
Phyllis S. Walker 
Introduction 
A recent California Blood Bank Society panel discussion of how often 
repeat testing should be done for chronically transfused, sensitized patients 
prompted a survey, the results of which are the subject of this paper. 
With the advent of the diagnosis-related groups (DRGs), some blood 
banks have been forced to lower their rates for reimbursement for serologic 
testing. This has led to decreased income, and in some cases a decrease 
in staffing. However, blood bankers are committed to high-quality patient 
care and safe transfusions and are trying to find more efficient and 
economical methods for pre-transfusion testing on the chronically trans- 
fused, sensitized patient. The serologic workup for these patients always 
requires more time, and we need more efficient ways to handle their 
transfusions without compromising quality. 
A survey of the regulatory agencies revealed that there are no guidelines 
to determine the standards of practice. The Food and Drug Administration 
is concerned with licensing establishments and products, manufacturing 
practices, biological product standards, standards of blood products, and 
standards of diagnostic reagents. It makes no recommendations about 
testing protocols.’ 
The state of California (California Administrative Code) is concerned 
with licensing laboratories and individuals, and with training schools, 
clinical laboratory standards, proficiency tests, and laboratory reports. It 
makes no recommendations about testing protocols. sup(2) 
Finally, the American Association of Blood Banks (AABB) publishes the 
Standards for  Blood Banks and Tranfusion Services, which does not 
include recommendations about how often to repeat the testing on 
chronically transfused, sensitized patients. It recommends screening reci- 
pients’ blood for unexpected antibodies, but there is no advice as to how 
frequently antibody identification should be repeated. sup(3) 
The goal of repeated antibody identification is easy to define. It is to 
determine whether the patient has made any new clinically significant 
antibodies. The answers to “How often should we test?” and “To what 
extent should we test?” are elusive. Since there are no specific regulations 
or recommendations, a survey of transfusion service laboratories and blood 
banks was made to determine the standards of practice. 
Materials and Methods 
A survey was sent to 167 transfusion service laboratories and donor 
centers in the state of California, and 142 (85%) responded. Of the in- 
stitutions surveyed, 14 were donor centers and 128 were hospitals. The 
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donor centers are blood collecting facilities that do not 3 .  Do you repeat the autocontrol as part of the pre- 
crossmatch blood; however, they offer reference transfusion testing? 
laboratory and consultation services to hospitals. The Donor Hosp. Hosp. Hosp. Hosp. 
data were subdivided in several ways, ie, large hospitals Total Centers <300 >300 No. CA. So. CA. 
(>300 beds) vs small hospitals ( <300 beds), and 
n=142 n=14 n=55 n=73  n=58 n=70 
hospitals-using Fresno, California, as an arbitrary NO 23% 14% 14% 31% 12% 33%) 
beds beds 
. northern California hospitals vs southern California 
dividing point between northern and southern Cali- Yes 75% 79% 82% 67% 84% 67% 
~~ 
fornia. This was done to compare the transfusion 
practice in different sized hospitals and. to look for 
regional differences in transfusion practice. The percen- 
tages in the tables of data were calculated by dividing 
the number of responses to an item by the total number 
of surveys (142) and multiplying by 100. In some caes 
the percentages per item may total more than 100%, 
and in other cases they may total less than 100%. This 
occurred when people responded to more than one 
choice, or when they failed to respond to any of the 
choices. The results of the survey follow. 
Results 
Subject: pretransfusion testing on chronically 
transfused, sensitized patients. 
1. Do you repeat A B 0  and Rh typing? If yes, on every 
Donor Hosp. Hosp. Hosp. Hosp. 
Total Centers <300 >300 No. CA. So. CA. 
beds beds 
n=142 n=l4 n=55 n=73 n=58 n=70  
No < 1% 0 n 3% 0 3% 
Yes 98% 93% 100% 97% 100% 97% 
specimen or periodically? 
Every 
specimen 96% 93% 96% 97% 98% 95% 
Period- 
ically <l% 0 2 %  n 0 2 %  
4.  Do you repeat the direct antiglobulin test (DAT) as 
part of pre-transfusion testing? 
_________ No 
_________ No, but we do the autocontrol 
_________ Yes 
Donor Hosp. Hosp. Hosp. Hosp. 
Total Centers <300 >300 No. CA. So. Ch. 
beds beds 
n=142 n=14 n=55 n=73 n=58  n=70 
No, auto 56% 43% 66% 51% 63% 53% 
Yes 24% 50% 18% 22% 24% 18% 
18% 27% 14% 30% No 21% n 
5. How often do you repeat antibody identification on 
known sensitized patients? 
_______ Every specimen 
_______ Every readmission to the hospital 
_______ Periodically, specify 
_______ When reactions (rx) appear stronger 
_______When antibody screening cells or donor 
cells are unexpectedly positive 
Donor Hosp. Hosp. Hosp. Hosp. 
Total Centers <300 >300 No. CA. So. CA. 
beds beds 
n=142 n=14 n=55 n=73 n=58 n=70 
Every specimen 
27% 14% 36% 22% 27% 29% 
Every readmission 
Periodically increased rx 
2 .Do you repeat the antibody screen? 27% 36% 30% 24% 27% 24% 
_______ No, we proceed directly to a panel if the pa- 
tient is-known to be sensitized 20% 0 20% 24% 20% 24% 
Unexpected rx 
______ Yes, on every specimen 
______ Yes, unless all screening cells are expected 54% 50% 48% 60% 57% 53% 
to he positive 
Donor Hosp. Hosp. Hosp. Hosp. 
Total Centers <300 >300 No. CA. So. CA. Donor Hosp. Hosp. Hosp. Hosp. 
beds beds Centers <300 >300 NO. CA. SO.  CA. 
beds beds n=142 n=14 n=55 n=73 n=58 n=70 
No 21% 50% 22% 13% 10% 23% Every 
Yes, 
every* 56% 36% 74% 46% 47% 
Yes, 
unless 10% 14% 4 %  13% 6% 
'Nine institutions reported using selected cells 
No. CA. < 300 beds 1 
No. CA. > 300 beds 2 
No. CA. Donor Center 1 
So. CA. < 300 beds 3 
So. CA. > 300 beds 2 
specimen 
67% 48 hours 
72 hours 









15 1 1 9 2 
1 5 4 2 9 
0 0 1 0 2 
0 1 2 5 0 
0 2 6 5 5 
0 1 1 0 3 
0 0 3 0 6 
0 0 1 0 2 
0 1 3 1 5 
0 1 0 1 0 
0 0 1 1 0 
1 0 4 4 0 
18 
6. If the patient has a chronically positive (IgG) DAT, 
how often do you perform an elution? 
______ Every specimen 
______ Only if transfused in the past three months 
______ Periodically, specify 
______ Not if a previous specimen yielded a non- 
______when the DAT is <1+ 
______When the DAT is 1+ or greater 
reactive or non-specific eluate 
Donor Hosp. Hosp. Hosp. Hosp. 
Total Centers <300 >300 No. CA. So. C A  
beds beds 
n=142 n=14 n=55 n=73 n=58 n=70 
12 % 7% 18% 9% 16% 11% 
Every specimen 
Transfused in past 3 months 
47% 50% 42% 49% 43% 48% 
Periodically, previously nonreactive/nonspecific 
DAT <  I +  
DAT 1+ 
23% 21% 16% 28% 25% 21% 
2% 7% 2% 1% 0 3% 
17% 7% 22% 15% 25% 12% 
Donor 
Centers 
Increased DAT 5 
Decreased 
hemoglobin 2 




































7. In a non-emergency situation, if antigen-negative 
donor units appear compatible by crossmatch, 
would you delay transfusion until antibody 
identification was completed? 
Donor Hosp. Hosp. Hosp. Hosp. 
Total Centers <300 >300 No. CA. So. CA 
beds beds 
n=142 n=14 n=55 n=73 n = 5 8  n=70 
Yes 79% 93% 76% 79% 71% 83% 
No 17% 0 18% 19% 27% 12% 
Discussion 
Although no attempt was made to analyze the data 
statistically, certain observations can be made about 
each question (listed here by question number). 
1. Almost all institutions repeat the ABO and Rh 
typing on every specimen. A report from one 
indicates that a forward and reverse ABO 
grouping is performed on the first specimen 
from a patient; however, only a reverse group- 
ing is performed on subsequent specimens. 
This would satisfy the need to confirm the 
identity of the specimen while reducing the 
workload and the volume of commercial an- 
tisera used. 
2. Fifty-six percent of the institutions indicate 
that the antibody screening test is repeated 
on every specimen. Selected cells are used in 
some laboratories while others immediately 
test a panel of cells. This is an area where 
efficiency may be increased. It is interesting 
to note that 74% of hospitals with fewer than 
300 beds repeat the antibody screening test 
on every specimen. 
3 & 4.  An autocontrol is included as part of the pre- 
transfusion testing in a majority of institu- 
tions; however, only 24% repeat the DAT as 
part of pre-transfusion testing. 
5. When to repeat antibody identification is an 
area that shows a complete lack of consen- 
sus in this survey. Even those institutions that 
indicate they repeat the antibody identifica- 
tion “periodically” lacked consensus about 
how often “periodically” means. 
It is surprising that 100% of the institutions 
do not repeat the antibody identification 
when reactions appear stronger or when an- 
tibody screening cells or donor cells are unex- 
pectedly positive. These are both indications 
of new sensitization. 
6. There is no clear consensus about how often 
to repeat an elution if a patient had a 
chronically positive DAT. Perhaps the most 
significant point is that elution is not repeated 
in 47% of the institutes surveyed unless the 
patient had been transfused in the past three 
months. Since transfused red cells do not per- 
sist in significant numbers after three months, 
a positive DAT at that point would represent 
autoantibody or be due to drugs. 
7 .  In a non-emergency situation, a majority of 
institutions indicated that an antibody iden- 
tification would be completed before transfus- 
ing the patient. The crossmatch would not 
be relied on to find compatible units. Since 
weakly reacting antibodies may show dosage 
and only react with red cells having a 
homozygous expression of the antigen, the 
crossmatch is not always a safe alternative to 
antibody identification. 
Comment 
The following suggestions are neither new nor 
original, but are simple and time-saving. They increase 
laboratory efficiency in antibody detection and iden- 
tification while maintaining safe transfusion practice. 
A. When a patient fist becomes a candidate for transfu- 
B. Select methods for antibody detection that avoid 
sion, identify all antibodies in the serum. 
known clinically insignificant antibodies. 
1. Cold autoagglutinins 
19 
a. Prewarmed technique ices, 12 ed. Arlington: American Association of Blood Ranks. 
b. Saline media 1987. 
c. using patient's plasma instead Of Serum 
d. Anti-IgG antiglobulin reagent 
4. Reid ME, Toy P. Simplified method for recovery of autologous 
red blood cells from transfused patients. Am J Clin Pathol 
1983;79:364-6. 
5 .  Widmann FK, ed. Technical manual. 9th ed. Arlington: 
American Association of Blood Banks, 1985. 
(reduces in vitro complement binding) 
2. Rouleaux 
a. Saline dispersal 
b. Saline replacement 
a. Anti-P sub(1): commercial substance or hydatid cyst 
b. Anti-Le: commercial substance or saliva 
c. Anti-Sd sup(a): urine 
Phyllis S Walker MS, MT(ASCP)SBB, Irwin Memorial Blood Bank, 
3. Neutralization 270 Masonic Avenue, PO Box 18718, San Francisco, CA 
94118-9990. 
fluid 
d. Anti-Ch sup(a), anti-Rg sup(a): serum/plasma 
C. Use time-saving approaches to identify clinically 
significant antibodies in sensitized patients. sup(5) 
1. Phenotype 
a. Recommended typings include: 
( 1 )  Rh: D, C, E, c (plus e if E + )  
(2)Kell: K (plus kif K + )  
(3)Duffy: Fy sup(a), Fy sup(b) 
(4)Kidd: Jk sup(a), Jk sup(b) 
(5)MNSs: S, s 
b. Red cell separation may be necessary to deter- 
mine the accurate phenotype if the patient has 
been recently transfused. sup(4) 
2. Select cells for antibody identification. 
a. Using the patient's phenotype, select panel cells 
with a homozygous expression of the antigens 
the patient lacks. 
b. If the patient appears to have an antibody to 
a high incidence antigen, it is essential to 
phenotype the red cells with appropriate 
reagents. Periodic testing with selected cells 
lacking the high incidence antigen should be 
done to look for new underlying antibodies. 
3. Reconfirm previously identified antibodies using 
a reagent red cell with a heterozygous expression 
of the antigen. 
It is not necessary to reconfirm the presence 
of known, clinically significant antibodies with 
reagent red cell panel studies; however, it may 
be time-saving and economical to include a 
known positive reagent red cell of heterozygous 
antigen expression along with donor units being 
crossmatched. If the reagent red cell with 
heterozygous antigen expression is positive with 
the patient's serum, crossmatch-compatible units 
may be considered antigen-negative; thus 
eliminating the need to type the donor units with 
commercial antiserum (see AABB Std. G4.110). sup(3) 
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COLD AUTOIMMUNE HEMOLYTIC 
SPECIFICITY: 51 CHROMIUM SURVIVAL 
STUDIES 
Mary H. McGinniss, Richard A. Binder, 
Arthur N. Kales, Richard J. Davey 
Abstract 
A 65-year-old woman was found to have severe auto- 
immune hemolytic anemia. The patient was group 
A , ,  Rh sub(o)(D) positive. The direct antiglobulin test was 
strongly positive with anti-C3 and negative with anti- 
IgG. The serum contained two distinct IgM antibodies, 
auto-anti-I and auto-anti-AI. Both were reactive at 22°C. 
However, the anti-AI also was reactive in saline and 
in albumin at 37°C. An eluate revealed anti-AI and a 
weak anti-I. Sequential sup(51)Chromium survival studies 
were done with group OI and AI red cells. The group 
OI red cells survived normally (97% at 24 hours) while 
the group A sub(1)I red cells were removed in a "two- 
component" pattern characteristic of IgM complement- 
fixing antibodies (62% survival at one hour, 49% at 
24 hours). Based on these observations, the patient was 
subsequently transfused without incidence with six 
group 0 units of washed red cells prior to splenectomy. 
Although auto-anti-AI has been previously reported, 
this is the first case to demonstrate the use of sup(51)Cr 
survival studies to determine its clinical significance. 
Introduction 
Cold reactive red cell autoantibodies are frequently 
detected at temperatures below 22°C. These cold 
reactive antibodies are of little clinical significance and 
are usually disregarded for transfusion purposes.' 
On occasion, cold autoantibodies display an 
unusually wide thermal range of reactivity that results 
in detection at physiologic temperatures. The clinical 
importance of these antibodies cannot be easily deter- 
mined unless careful clinical and serological assessment 
ANEMIA WITH AUTO-ANTI-AI 
1.  Code of Federal Regulations (21-CFR); 1985: Part 600, Food and 
Drug Administration. 
2 California Administrative Code; Register 82,  Title No  17 (Clinical 
Laboratory Regulations), 1982, Department of Public Health, 
State of California. 
3 .  Schmidt PJ. ed. Standards for blood banks and transfusion sew- 
of individual is undertaken, 
We present a case in which differential serological 
testing and sup(51)Cr survival studies determined the 
transfusion protocol for a patient with auto-anti-AI in 
her serum. 
20 
